Results 221 to 230 of about 38,769 (305)

Real-World Association of SGLT2 Inhibitors with Mortality in Very Elderly Patients with HFrEF and CKD. [PDF]

Biomedicines
Bollas Becerra AJ, García MC, Balaguer Germán J, Rodríguez-López C, Romero Otero JM, Esteban Chapel JA, Nieto Roca L, Taibo Urquía M, Pello Lázaro AM, Tuñón J.   +9 more
europepmc   +1 more source

Impact of SGLT2 Inhibitors on Mortality Across Different Populations: A Systematic Review and Meta-Analysis. [PDF]

Int J Mol Sci
Movila DE, Motofelea AC, Dragan SR, Schiller A, Ionac A, Motofelea N, Caruntu F.   +6 more
europepmc   +1 more source

Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub‐analysis of Hokkaido‐TZP study data

Journal of Diabetes Investigation, EarlyView.
Tirzepatide achieved significant HbA1c reduction in Japanese patients with type 2 diabetes without obesity, regardless of baseline BMI. Weight reduction was BMI‐dependent and enhanced by dietary consultations. No patient developed underweight status during the 6‐month observation period.
Tomoe Abe, Fumika Maruyama, Eisuke Nishikawa, Miki Ito, Yukie Miyano, Hiroki Yamagata, Taiga Sasaki, Hidemitsu Sakagami, Akinobu Nakamura, Hiroshi Nomoto, on behalf of the Hokkaido‐TZP Study Group   +10 more
wiley   +1 more source

Monocyte dipeptidyl peptidase 4 activity is associated with urinary albumin excretion in type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
This study examined whether dipeptidyl peptidase 4 (DPP4) characteristics in peripheral blood monocytes relate to renal parameters. Monocyte DPP4 activity was independently associated with urinary albumin excretion in patients with type 2 diabetes, suggesting that monocytes may function as a cellular link between DPP4 and diabetic kidney disease ...
Hideyuki Okuma, Takahiro Tsutsumi, Kyoichiro Tsuchiya   +2 more
wiley   +1 more source

Barriers to prescribing and insurance approval of SGLT2 inhibitors for heart failure: a mixed-methods study in Jordan. [PDF]

Front Pharmacol
Merdas ZJH, Abed A, Abu Assab M, Abu Dayyih W, Bustami M, Saudi LM, Shilbayeh SAR.   +6 more
europepmc   +1 more source

SGLT2 independent effects of the SGLT2 inhibitor empagliflozin

This thesis explores how sodium glucose cotransporter 2 inhibitors (SGLT2i), particularly empagliflozin (EMPA), reduce cardiovascular risk by investigating their effects on cardiac infarction, hypertrophy, and heart failure (HF). SGLT2i demonstrate significant cardiovascular benefits across diabetic and non-diabetic populations, possibly through off ...
openaire   +2 more sources

Comment on ‘Glycemic control and renal function decline in patients with chronic coronary syndrome: A multicenter cohort study’

Journal of Diabetes Investigation, EarlyView.
Jiandi Li
wiley   +1 more source

Effects of Oral Single‐Dose Empagliflozin on Urinary Glucose, Serum β‐Hydroxybutyrate, and Plasma Empagliflozin Concentrations in Healthy Adult Dogs

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Empagliflozin is a sodium‐glucose cotransporter‐2 inhibitor used for treating humans with heart failure, among other conditions. This drug could have applications in veterinary cardiology, but whether empagliflozin has biological effects in dogs when administered at dosages approximating human therapeutic dosages is unknown.
Andrea D. Plá Gutierrez, M. Lynne O'Sullivan, Etienne Côté, Sandra McConkey, Butch KuKanich, Stephanie E. Martinez   +5 more
wiley   +1 more source

Efficacy of SGLT2 inhibitors in preventing end-stage kidney disease in patients with IgA nephropathy: a scoping review. [PDF]

Front Med (Lausanne)
Phongphithakchai A, Klangbud WK, Srithongkul T, Raksasuk S, Chatatikun M.   +4 more
europepmc   +1 more source